Reaction
Central Serous Chorioretinopathy reporting signals
As of the last recalculation, Central Serous Chorioretinopathy appears in 610 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05% (PRR 113.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Triamcinolone Acetonide Ointment Usp, 0.05% | 69 | 113.3 | 113.6 |
| Triamcinolone Acetonide | 69 | 85.8 | 86.0 |
| Testosterone | 45 | 70.8 | 71.0 |
| Encorafenib | 16 | 56.6 | 56.7 |
| Minoxidil Foam 5% (Womens) | 32 | 34.9 | 34.9 |
| Methimazole | 7 | 30.8 | 30.8 |
| Clobetasol Propionate Ointment Usp, 0.05% | 9 | 30.2 | 30.3 |
| Clobetasol Propionate | 9 | 30.1 | 30.2 |
| Minoxidil | 32 | 25.6 | 25.6 |
| Dexamethasone Sodium Phosphate | 7 | 23.8 | 23.8 |
| Vemurafenib | 6 | 17.2 | 17.2 |
| Faricimab | 4 | 16.9 | 17.0 |
| Aflibercept | 12 | 13.4 | 13.4 |
| Remdesivir | 5 | 12.9 | 12.9 |
| Voclosporin | 3 | 11.8 | 11.8 |
| Dabrafenib | 7 | 11.5 | 11.5 |
| Trametinib | 8 | 11.4 | 11.4 |
| Ranibizumab | 7 | 9.1 | 9.1 |